Topic: ESOPRS 2021 ePoster sessions
Time: Sep 17, 2021 16:00 Amsterdam, Berlin, Rome, Stockholm, Vienna, 15:00 London
The zoom session will be a MEETING. Please turn off your camera and mic, unless prompted by the moderators during Q&A. When you enter the meeting there will be 2 BREAKOUT ROOMS. Please choose the appropriate room to join once you have joined the meeting.
The link details are below (you need to be logged in)
You are currently not logged in. If you have an account on this website please login to your account. Not registered yet? Signup here
(plain text version here)
An update on Idiopathic Canalicular Inflammatory Disease
Author: Nandini Bothra
ePoster Number: 130
To propose a modified treatment protocol for patients with diagnosed idiopathic canalicular inflammatory disease (ICID).
A prospective interventional study involving 88 canaliculi of 44 eyes of 22 patients who were diagnosed with ICID over a period of 2 years. All patients were initially treated with a combination of rapidly tapering topical steroids and topical cyclosporine eyedrops followed by punctal dilatation and mini-monoka stents when needed once the inflammation was under control. Stent extubation was done at 6 weeks and topical cyclosporine was continued for further 3 months. Patient demographics, staging of the disease, response to treatment, anatomical and functional outcomes were analyzed.
88 canaliculi with ICID were diagnosed during the study period. There was female preponderance (77%) and mean age at presentation was 51 years. All patients presented with bilateral epiphora. Staging revealed 18,27,24,19 canaliculi was involved with stages 1-4 respectively. Cyclopsorine was used for a mean of 5.7 months. All patients except 3 underwent monoka dilatation. Complete anatomical and functional resolution was noted in 62% cases of which 13.6% (stage 1) showed resolution with topical cyclosporine alone. Disease progression to stage 5 was noted in 30% cases. Younger patients (<30 years, 13.6%, 3/22) demonstrated poorer outcomes.
The addition of topical cyclosporine is beneficial in controlling inflammation and disease downstaging in patients with ICID. The current modified treatment protocol salvages majority of the canaliculi.
|First name||Last name||Base Hospital / Institution|
|Mohammad||Javed Ali||LV Prasad Eye Institute|
Abstract ID: 21-157